Search AMIA.org

Artificial intelligence (AI) is increasingly being deployed in health-care settings, yet health systems remain at an early stage in developing approaches to scale effective applications. Much of current activity is characterized by early-stage use cases and pilot projects. In this study, we explored how different health systems are approaching the development, adoption, implementation, and scaling of AI in healthcare to identify transferable lessons for system-level change.

To systematically examine different clinical data modalities in large language models (LLMs) and multimodal large language models (MLLMs), and to quantify the contribution of data modalities in early inpatient risk prediction and decision support tasks.

Human Factors (HF) principles are essential for safe and effective clinical decision support (CDS), yet existing guidance is fragmented and rarely evaluated in real world settings. A novel, evidence-based, vendor-agnostic HF-informed guideline was developed to address this gap. This study evaluated its perceived usefulness, usability, and impact on CDS design and optimization.

This study aimed to identify trajectories of multimorbidity following acute myocardial infarction (AMI), using explainable temporal machine-learning methods, and assess their clinical, prognostic, and biological significance.

The potential of "big data" in health research remains largely untapped, particularly concerning real-world data sources such as administrative health data and electronic medical records. While healthcare insurance claims data have been essential for assessing medication safety and effectiveness within indicated patient populations, exploring broader drug-outcome associations could uncover significant insights.

To develop and systematically compare a human-led and LLM-assisted hybrid deductive-inductive workflow for qualitative analyses.

We audited deployment readiness of an end-of-surgery postoperative infection model across clinically relevant subgroups and assessed mitigation of subgroup miscalibration.

To assess whether external validation and clinical implementation of clinical prediction models reflect sequential or distinct stages of a translational pathway.